Abstract Examining for new BC biomarkers has proven that kallikrein-related peptidase (KLK) family members represent promising serum and/or tissue molecular tools for early diagnosis, effective prognosis, and treatment monitoring of patients. The aim of this study was to investigate, the previously unexplored, prognostic significance of KLK8 in BC. KLK8 mRNA expression was quantitatively analyzed in 150 cancerous and 100 corresponding normal breast tissue specimens via a SYBR Green-based RealTime PCR methodology. Expression data and patients' clinicopathological parameters were used for extensive biostatistical analyses, including internal validation. KLK8 mRNA expression was significantly downregulated in the cancerous tissue part relative to the non-cancerous counterpart (P \ 0.001), in the majority of the paired breast tissue samples. KLK8 expression was associated with advanced TNM stage (P = 0.019) and positive nodal status involvement (P = 0.044). Triple negative (TNBC) and HER2 overexpressing tumors exhibited higher KLK8 expression levels (P \ 0.001), compared to Luminal A and B molecular subtypes. Kaplan-Meier survival curve analysis revealed that BC patients with high KLK8 expression had significantly shorter disease-free survival (DFS) intervals (P \ 0.001) compared to those belonging in the KLK8-low expression group. Cox univariate analysis confirmed the association between KLK8 expression, analyzed as a continuous variable, and poor patients' outcome (Hazard ratio [HR] = 3.28, P \ 0.001). Most importantly, multivariate analysis showed that KLK8 expression is a strong and independent predictor of adverse DFS in BC ([HR] = 2.74; P = 0.002). Our results show that KLK8 mRNA expression is associated with aggressive tumor characteristics and it can serve as a novel independent biomarker of unfavorable prognosis for BC patients. 
Introduction
One of the major hurdles in improving breast cancer (BC) patients' management is the remarkable molecular and biological heterogeneous nature of the disease, which in turn results in distinct clinical presentations and behaviors of the tumors [1] . Although the routinely used clinicopathological factors of prognosis in BC, such as histological stage and grade, steroid hormonal receptors' (estrogen (ER) and progesterone (PR) receptors), and human epidermal growth factor receptor 2 (HER2) status, are highly useful [2] , it is now apparent that these parameters have a limited capacity to predict the intrinsic complexity of BC and to tailor individual treatment [1] . Therefore, contemporary research efforts are focused towards the identification of novel and more reliable BC-specific biomarkers which can be found among the biomolecules that play key roles in fundamental processes underlying cancer establishment and progression, including members of the family of kallikrein-related peptidases (KLKs).
Kallikrein-related peptidases (KLKs) are fifteen closely related secreted serine proteases, which are expressed in a broad spectrum of human tissues and are involved in a plethora of physiological activities [3] [4] [5] . Many studies provide evidence that the deregulated KLK expression and/or function is a common event in human malignancies [6, 7] and notably, BC development and KLKs are closely related as well. In particular, KLK3, KLK6, and KLK10 display tumor suppressive characteristics, whereas KLK1 and KLK11 exhibit tumor promoting effects during BC progression [6, [8] [9] [10] [11] [12] .
The KLK8 gene, which maps to the human kallikrein multigene cluster, encodes for serine protease with trypsinlike activity [13] . Several experimental data propose distinct mechanisms, by which KLK8 participates in tumor progression. Rajapakse et al. showed that KLK8 can efficiently degrade a number of ECM proteins such as collagen type IV and fibronectin, and thereby facilitates pericellular proteolysis and cancer cell invasion. The same study also revealed that KLK8 is able to activate single-chain tissuetype plasminogen activator (tPA), which in turn generates plasmin from plasminogen. Plasmin also plays an important role in ECM remodeling, either directly through its own activity or indirectly via the activation of MMPs [13] . Contrariwise, Sher et al. demonstrated that overexpression of KLK8 suppresses the invasiveness of lung adenocarcinoma cells in vitro and inhibits tumor growth and invasion in vivo. This finding was attributed to the degradation of fibronectin by KLK8, which interferes with the fibronectinintegrin signaling pathway and reduces tumor cell motility by preventing actin polymerization [14] .
KLKs are being actively investigated for their clinical value as molecular tumor markers [15, 16] and KLK8 has been proposed as a promising prognostic biomarker for ovarian [17] [18] [19] and lung cancer [14, 20] . Although previous studies have revealed that KLK8, like most of the KLK genes, is downregulated in BC compared with noncancerous breast tissues [21, 22] , no data have been reported concerning its possible prognostic importance in BC.
Therefore, the aim of this study was the comprehensive mRNA expression analysis of KLK8 in breast tumors and adjacent non-cancerous breast tissues and the investigation of its previously unexplored, clinical usefulness and prognostic significance as a novel molecular tissue biomarker for BC.
Materials and methods

Collection of breast tissue samples and clinical data
A total of 150 breast tumor specimens and 100 matched non-malignant breast tissue sections were collected during routine therapeutic surgery of patients with newly diagnosed BC, at the ''Saint Savvas'' Anticancer Hospital of Athens, between 2010 and 2011. Immediately after resection, each malignant and corresponding normal breast tissue sample was histopathologically characterized and stored at -80°C until use. This study was designed according to new guidelines for reporting new tumor biomarkers [23] and it was approved by the institutional review board of ''Saint Savvas'' Anticancer Hospital. Research procedures of this study complied with the ethical standards of the World Medical Association's Declaration of Helsinki. All participants provided written informed consent prior to breast tissue harvesting. None of the patients had received pre-operative (neoadjuvant) treatment.
Patient characteristics and tumor clinical and histopathological features were also provided for statistical analyses. Tumors were staged according to tumor-node-metastasis (TNM) classification and graded based on the Bloom-ScarffRichardson grading system (Supplementary Table S1 ).
Adjuvant systemic treatment was administered to BC patients according to the guidelines of ''Saint Savvas'' Anticancer Hospital and the respective consensus recommendations at the time. In particular, 28 (18.7 %) patients were treated with endocrine therapy alone; 43 (28.7 %) patients were given chemotherapy alone; 48 (32.0 %) patients had a combination of chemotherapy and endocrine therapy, and 19 (12.7 %) patients underwent adjuvant treatment with HER2-targeted therapy in addition to chemotherapy. Different treatments are shown in Supplementary Table 1. BC-specific disease-free survival (DFS) information were available for 124 patients. DFS was defined as the time interval between the surgical resection of the tumor and the date of the first documented event of either local or regional recurrence, second cancer, or death from BC, and was used as an endpoint in the statistical survival analyses [24] . Table 1 summarizes clinicopathological information of the samples and patients' characteristics.
Immunohistochemical (IHC) assessment of hormone receptors' expression, HER2 status, and Ki67 labeling index
The expression of ER, PR, HER2, and Ki-67 labeling index in BC tissue samples was determined by IHC staining in the pathology laboratory of ''Saint Savvas'' Anticancer Hospital. The antibodies used were for ER (Dako 1D5), PR (Dako PgR636), HER2 (Dako polyclonal rabbit anti-human c-erbB2), and Ki67 (Dako MIB1).
ER and PR were scored semiquantitatively on the basis of both the staining intensity (i) and the corresponding percentage of positive-stained cells (Pi), using the equation Hscore = R (Pi 9 i/100). The cutoff for positivity of Hscore was 0. 35 [25] . For the nuclear antigen Ki67, the percentage of positively stained nuclei was calculated. The cutoff value for Ki67 labeling index was considered as 14 % of positive cancer nuclei, in order to distinguish tumors with low (\14 %) and high (C14 %) proliferative fraction [26] .
Furthermore, according to the St. Gallen expert consensus, breast tumors can be classified into distinct molecular subtypes based on IHC staining results for estrogen and progesterone receptor status, IHC or in situ hybridization tests for the detection of overexpression and/ or amplification HER2 and Ki67 labeling index. Therefore, the above-mentioned assessments were used to categorize breast tumors into: luminal A (ER? and/or PR?, Ki67 low and HER2-), luminal B (ER? and/or PR?, Ki67 high and/or HER2?), HER2-overexpressing (ER-, PR-and HER2?), and triple negative (ER-, PR-, and HER2-) subtypes [1, 26] .
Total RNA extraction, RNA quality evaluation, and cDNA synthesis Approximately 50-100 mg of each deep-frozen breast sample, were pulverized to a fine powder and homogenized by the addition of 1 mL of TRI reagent Ò (Molecular Research Center). Following the manufacturer's instructions, total RNA was extracted, diluted in RNA Storage Solution (Applied Biosystems), and stored in -80°C. For all samples, total RNA purity and concentration were determined spectrophotometrically and RNA integrity was visually confirmed using agarose gel electrophoresis. Single-stranded cDNA synthesis was performed from 2 lg of total RNA, using M-MuLV reverse transcriptase (Invitrogen), recombinant RNase inhibitor (Invitrogen), and oligo (dT) 18 primer, in a final reaction volume of 20 lL. Quantitative real-time PCR (RT-qPCR)
The quantification of KLK8 mRNA expression levels was performed by RT-qPCR, using the SYBR Green chemistry on a 7500 fast real-time PCR system (Applied Biosystems). Gene-specific primer pairs were designed based on the published cDNA sequences of the reference gene HPRT1 (NM_000194.2), and the KLK8 type 1 mRNA transcript variant, which encodes the canonical 260-amino acid KLK8 protein (NM_007196.3). The primer sequences used in this study were as follows: KLK8 forward 5 0 -GGAGCCTGGG CAGGACAC-3 0 and reverse 5 0 -AAGGACACCGCCACAG AGTAGTT-3 0 (PCR amplicon of 129 bp); HPRT1 forward 5 0 -TGGAAAGGGTGTTTATTCCTCAT-3 0 and reverse 5 0 -ATGTAATCCAGCAGGTCAGCAA-3 0 (PCR amplicon of 151 bp). We selected HPRT1 as a housekeeping gene for data normalization as it was previously identified as the most suitable single endogenous control gene for expression studies in various solid tumors, including BC [27] .
The RT-qPCR reaction mixture consisted of 10 ng of template cDNA, 5.0 lL Kapa SYBR fast qPCR Master Mix (Kapa Biosystems), 0.2 lL of 509 Rox low passive reference dye (Kapa Biosystems), 1.0 lL of gene-specific primers (final concentration KLK8: 350 nM; HPRT1: 300 nM), adjusted to a final volume of 10.0 lL with DEPC-treated water. All genes were amplified in technical triplicates for each sample, using the following thermal cycling conditions: an initial step at 95°C for 3 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. After the completion of RT-qPCR cycles, melting curves of amplified products were generated in order to verify the reaction specificity and the absence of primer dimers and/or contamination. In addition, randomly selected RT-qPCR products were electrophoresed on 3.0 % (w/v) agarose gel and visualized, under UV light, after ethidium bromide staining.
The relative quantification of KLK8 mRNA expression was performed using the comparative threshold cycle (DDCt) method. Relative quantification units (RQ units) of KLK8 in each sample were calculated based on the equation:
. The DCt is the difference between the Ct value of the target gene and the endogenous control [DCt = Ct (KLK8) -Ct (HPRT1)] and DDCt is the difference between the average DCt value of an experimental sample and the average DCt of the corresponding calibrator [DDCt = DCt (sample) -DCt (calibrator)] [28] . In the current study, the human BC cell line BT-474 served as a calibrator.
The main requirement for the application of the comparative Ct method is that the amplification efficiencies of the target and reference genes are approximately equal and close to 100 %. Therefore, validation experiments were carried out using a tenfold dilution series of calibrator cDNA, covering several orders of magnitude, for the generation of standard curves by plotting Ct values vs log of input cDNA. The RT-qPCR efficiency (E) was calculated from the slope of the standard curves according to the formula: E = (10 (-1/slope) -1) 9 100.
Statistical analyses
The KLK8 expression data and patients' clinicopathological characteristics were subjected to extensive biostatistical analyses using the SPSS software program (SPSS Inc., version 17.0). The nonparametric Wilcoxon signed-ranks test was applied to analyze the differences of KLK8 mRNA expression in the pairs of matched non-cancerous and tumor counterparts. We also used the Oncomine database [29] to determine whether KLK8 mRNA expression is deregulated in clinical BC samples compared to noncancerous breast tissues, based on microarray gene expression profiling studies employing established patient datasets. Moreover, the correlations between continuous variables of the study were examined with Spearman correlation coefficient (r s ). The Mann-Whitney U, Jonckheere-Terpstra, and Kruskal-Wallis tests were employed to scrutinize the differences of KLK8 expression between distinct groups of BC samples. The capability of KLK8 levels to distinguish triple negative breast tumors (TNBC) from other molecular BC subtypes was evaluated via the construction of Receiver operating characteristic (ROC) curve, by plotting sensitivity versus (1-specificity) values.
The area under the curve (AUC) was analyzed using the Hanley and McNeil method. We also applied the X-tile algorithm [30] in order to dichotomize BC patients into KLK8-low and KLK8-high expression populations. X-tile plots allowed the determination of an optimal cutoff value for KLK8 expression data based on DFS, while correcting for the use of minimum P value statistics. Corrected P values for the cutoff points were calculated using the Miller-Siegmund P value correction and Monte Carlo simulations (e.g., Cross-validation) based on 1000 random populations. The software also splits the entire population cohort into random training and validation subsets, and subsequently finds the appropriate cutoff in the training set and then applies this cut-point in the validation cohort, allowing in this way the internal validation of the results. The cutoff point calculated by the above-mentioned approaches was defined as 4.68 RQ units of KLK8 expression (69th percentile). KLK8 mRNA expression was also analyzed as a continuous variable in order to minimize the loss of information due to categorization. Survival analysis was done by constructing Kaplan-Meier DFS curves and significance was evaluated using the log-rank test. Both univariate and multivariate Cox proportional hazard regression models were developed in order to determine the prognostic value, with respect to DFS, of KLK8 expression and other clinical parameters. The multivariate regression model was adjusted for established clinicopathological and demographic variables including TNM stage, lymph node status, histological grade, BC molecular subtype, and patients' age. Moreover, we developed a separate multivariate model which included KLK8 expression and the different adjuvant treatment modalities used (chemotherapy and endocrine therapy).
We next performed a complementary statistical approach, in order to analyze the prognostic value of KLK8 mRNA expression in subgroups of patients, stratified according to the type of systemic adjuvant treatment received. Thereafter, Kaplan-Meier survival analysis was done for each patient subgroup (i.e., adjuvant chemotherapy-treated, no chemotherapy-treated, adjuvant endocrine-treated, and no endocrine-treated). A P value of less than 0.05 was considered as an indication of statistical significance.
Results
Quality control of the RT-qPCR assay for the quantification of KLK8 mRNA expression Gene-specific amplification was confirmed by the presence of a single peak with the appropriate melting point temperature (T m ) for each amplicon (KLK8 T m = 86.3°C; HPRT1 T m = 81.5°C) ( Supplementary Fig. 1A and B) and by the appearance of a single band, of the expected amplicon size, in the agarose gel electrophoresis analyses ( Supplementary Fig. 1C) .
The RT-qPCR amplification efficiencies for the reference and target gene were calculated from the slopes of the corresponding standard curves deriving from validation experiments. The slopes of HPRT1 (-3.344; R 2 = 0.999) and KLK8 (-3.402 0; R 2 = 0.996) standard curves were similar ( Supplementary Fig. 1D ), and the calculated PCR amplification efficiencies were 99.0 and 96.7 % correspondingly, thereby allowing relative quantification by the application of the 2 -DDCt formula.
Downregulation of KLK8 mRNA expression in cancerous compared to matched histologically normal breast tissues
The expression of KLK8 was investigated in 100 paired specimens of cancerous and matched histologically normal breast tissues located adjacent to the carcinoma. This analysis revealed that KLK8 mRNA expression levels were significantly downregulated in BC tissue sections compared to the non-cancerous component in 72 % of the cases examined, whereas only 28 % of the paired samples exhibited higher KLK8 expression in the cancerous part than their corresponding non-tumor breast tissues (P \ 0.001; Wilcoxon signed-ranks test; Fig. 1a ).
Using the oncomine database, we observed that KLK8 expression levels were substantially downregulated in the majority of BCs of different subtypes, relative to nonmalignant breast tissues (Fig. 1b) .
KLK8 mRNA expression is associated with advanced TNM stage, lymph node positive status, and triple negative breast tumors (TNBC)
In the next step of our study, we investigated the associations between KLK8 mRNA expression levels in BC tissues with the clinicopathological parameters of the patients examined. Our data showed that KLK8 expression is 
associated with several clinicopathological features, indicative of unfavorable prognosis in BC patients (Table 2 ). In particular, KLK8 mRNA expression levels had an increasing trend with the progression of the tumor TNM stage (P = 0.019) (Fig. 2a) . The median KLK8 expression in the group of patients with clinical stage III or IV (5.18 RQ units) was remarkably higher compared to TNM stage II (2.31 RQ units), and stage I or 0 (2.16 RQ units) tumors. Furthermore, a significant positive relationship between KLK8 expression with positive nodal status was also observed (P = 0.044). KLK8 mRNA expression differed remarkably (P = 0.002; Kruskal-Wallis Test) between BC molecular subtypes (Fig. 2b) . Moreover, KLK8 mRNA expression was found to be significantly increased (P = 0.009) in the group of patients with TNBC (median 3.85 RQ units) tumors compared to those with other BC molecular subtypes (median 1.64 RQ units). ROC curve analysis revealed the ability of KLK8 mRNA expression to distinguish patients with TNBC from patients harboring breast tumors of other molecular subtypes ([AUC] = 0.653, [95 % CI] = 0.546-0.760, P = 0.009) (Fig. 2d) . High KLK8 levels were also found in TNBC and HER2 overexpressing groups (collectively non-luminal subtypes) compared to luminal A and B (luminal subtypes) ones (P \ 0.001) (Fig. 2c) . The median KLK8 expression in the group of patients with non-luminal BC subtypes (4.47 RQ units) was substantially higher compared to luminal (1.59 RQ units) carcinomas.
On the contrary, no significant association was found between KLK8 expression and tumor grade, HER2 status, Ki67 proliferative index, or patients' age. Using the Spearman correlation coefficient analysis we also observed a weak negative correlation between KLK8 mRNA levels and ER (r s = -0.281; P = 0.001) and PR (r s = -0.273; P = 0.001) expression, in breast tumors. No correlations were observed between KLK8 expression and other continuous variables such as tumor size, patients' age, and Ki67 labeling index.
Internal validation of the prognostic significance of KLK8 based on an optimal cutoff value The X-tile algorithm generated an optimal cutoff value equal to the 69th percentile (4.68 RQ units) of KLK8 expression that was able to effectively dichotomize our patient cohort based on DFS analysis, while correcting the chance of type I errors (Miller-Siegmund P \ 0.001). The significance of the selected cutoff point was reinforced by Monte Carlo simulations based on 1000 random populations (Cross-validation P = 0.0010, Monte Carlo corrected P \ 0.001). Moreover, the patients' cohort was randomly divided into training and validation subsets (2:1 patient population ratio), in order to perform internal validation. The above-mentioned selected cutoff was identified as optimal in the training cohort (P = 0.0012), and after its application in the validation cohort it also reached high statistical significance (P = 0.014).
KLK8 expression is associated with poor DFS of BC patients
Next, we aimed to investigate the possible prognostic value of KLK8 expression status in the entire BC patients' cohort. For this purpose, we initially performed Kaplan-Meier DFS curve analysis with log-rank test for determining statistical significance. Notably, patients with BC belonging to the KLK8-high expression group had significantly (P \ 0.001) shorter DFS intervals compared to patients in the KLK8-low expression group (Fig. 3) . The 3-year cumulative probability of BC-specific DFS for patients belonging to the KLK8-high group was 0.561 whereas the corresponding probability for patients in the KLK8-low group was 0.931. Using univariate Cox regression analysis, we further confirmed the unfavorable prognostic value of KLK8 expression, with respect to DFS, in BC patients. Firstly, analysis was performed using KLK8 mRNA expression as a continuous variable (log-transformed values of RQ units). As shown in Table 3 Additional clinicopathological variables, including clinical TNM stage, BC molecular subtype, tumor size, and lymph node status were also strongly associated with poor DFS of BC patients (All HR[1.0, and P values\0.05; Table 3 ).
KLK8 expression is an independent predictor of unfavorable prognosis in BC patients
The independence of KLK8 expression in predicting unfavorable outcome in BC patients was also evaluated using Cox multivariate analysis. In particular, after adjustment for important clinicopathological factors including TNM stage, nodal status, BC molecular subtype, histological grade, and patients' age, KLK8 mRNA expression, as a continuous variable, was found to be a strong independent predictor of adverse prognosis for BC patients with a hazard ratio of 2.69 ([95 % CI] = 1.42-5.12, P = 0.003). Moreover, we repeated the analysis described above using KLK8 expression as a binary variable. Again, high-KLK8 expression retained its independent unfavorable prognostic nature with a hazard ratio 4.54 ([95 % CI] = 1.64-12.57, P = 0.004) ( Table 4) .
Moreover, a separate multivariate model which included KLK8 mRNA expression and the different adjuvant treatment modalities (chemotherapy; endocrine therapy) was developed. Interestingly, after correcting for adjuvant treatment, KLK8 mRNA expression retained its independence as an indicator of unfavorable outcome for BC patients KLK8 mRNA expression is associated with unfavorable DFS in subgroups of BC patients, stratified according to the type of adjuvant systemic therapy received
In order to evaluate the prognostic relevance of KLK8 mRNA expression regarding DFS in subgroups of patients based on the adjuvant systemic therapy received, a stratified KaplanMeier survival curve analysis was performed. In both, adjuvant chemotherapy-treated and endocrine-treated subgroups, patients with high-KLK8 mRNA expression presented a significantly shorter DFS (chemotherapy-treated P = 0.003; endocrine-treated P = 0.001), compared to those categorized as KLK8-low. In patients who had not received adjuvant chemotherapy, high-KLK8 was also associated with shorter DFS intervals reaching statistical significance (P = 0.016). However, in the subgroup of patients who did not receive adjuvant endocrine treatment, no impact of KLK8 expression status on DFS was observed (P = 0.204) (Fig. 4) .
Discussion
In the present study we quantitatively analyzed KLK8 mRNA expression in breast tumors and matched histologically normal tissue sections, in order to investigate the Fig. 3 Kaplan-Meier disease-free survival curve for the whole cohort of 124 BC patients. Patients were categorized as KLK8-high or KLK8-low expression groups according to the optimal cutoff value (69th percentile). P value was calculated via the log-rank algorithm possible associations with clinicopathological features of the patients, and to further assess its prognostic performance in BC with respect to prediction of disease progression. To the best of our knowledge, this is the first study examining the clinical relevance of KLK8 mRNA expression, in breast carcinomas.
Our data demonstrate that KLK8 expression levels are significantly (P \ 0.001) downregulated in BC tissue parts compared to adjacent histologically normal counterparts in the majority (72 %) of paired breast specimens examined. We next performed in silico expression analysis using information from the Oncomine expression profiling database, which revealed that KLK8 mRNA expression is markedly decreased in breast carcinomas than in normal breast tissues, corroborating our findings. These observations are in agreement with previous studies showing that most of the KLK family members, including KLK8, exhibit reduced mRNA and/or protein expression levels in breast tumors compared to non-malignant breast tissues [21, 22, 31] . In particular, Yousef et al., using a small set of BC and normal tissues showed that KLK8 mRNA levels were lower in tumors than in non-cancerous breast tissues [22] . A recent study using massively parallel signature sequencing (MPSS) and isolated epithelial cells from BC and normal counterparts revealed that KLK8, along with KLK5, KLK7, KLK10, is among the set of genes which are significantly downregulated in the tumor epithelial transcriptome [32] . Several reports show that molecular mechanisms, such as epigenetic modifications and specifically DNA hypermethylation, may contribute to the downregulation of KLK gene expression in BC [33] . One characteristic example is the tumor-specific KLK10 exon 3 hypermethylation in BC cell lines and tissues [34, 35] . Therefore, we may speculate that changes in DNA methylation could partially account for the deregulation of KLK8 expression in breast tumors. According to our data, KLK8 mRNA expression was found to be associated with important indicators of poor prognosis in BC and with more aggressive forms of the disease. In more details, KLK8 mRNA levels were increased in a statistically significant degree (P = 0.019) in the group of patients with advanced TNM stage (III/IV) compared to those with TNM stage II or I breast tumors. In addition, KLK8 expression was found to be associated with positive nodal status of the patients (P = 0.044). We also observed a weak negative correlation between KLK8 and ER (r s = -0.281; P = 0.001) and PR (r s = -0.273; P = 0.001) levels of expression. Another important finding of our present research was the remarkable higher expression levels of KLK8 in TNBC, compared to other molecular subtypes of disease. The differential diagnostic potential of this observation was also demonstrated by ROC curve analysis (AUC = 0.653; P = 0.009). Interestingly, mRNA expression of KLK8 was significantly (P \ 0.001) higher in non-luminal breast carcinomas (TNBC and HER2 overexpressing tumors) than luminal subtypes (luminal A and B) of BC. Generally, nonluminal BC molecular subtypes, and particularly TNBC, are associated with worse overall and disease-free survival rates compared to luminal disease [36] [37] [38] . Therefore, it is tentative to say that KLK8 expression may be used in conjunction with established molecular markers in order to refine BC molecular classification and to improve treatment selection for individual patients. Supporting this hypothesis, the basal-like group of tumors, which typically lack or show low levels of hormone receptors and HER2 expression [38] , exhibit high expression of a unique cluster of genes that are usually found in the basal epithelial cell layer. These include among others keratins 5, 6, and 17 and four KLKs, including KLK8 [39] . Additionally, Glynn et al., using microdissected BC epithelium from high nitric oxide synthase ER-negative tumors also showed that KLK8 was among the basal-like signature genes [40] . Furthermore, given on the one hand the recognition that gene expression signatures have the potential to identify molecular changes that can be used to predict recurrence of disease as well as response to specific therapies and on the other, the rapid rise in interest in developing multigene prognostic and predictive tools, such as real-time PCRbased assays (e.g., Oncotype DX and PAM50) and microarray-based multigene tests (e.g., MammaPrint) [41] , one might consider the inclusion of KLK8 into multifactorial biomarker panels and/or other multigene assays that may contribute in the multidimensional approach which is required for optimal management of BC patients. Interestingly, data from a ''four-kallikrein panel'' are very encouraging for prostate cancer patients' management and several multicomponent KLK-based panels have been described for other cancers as well (e.g., ovarian and lung cancer) [15] .
According to Kaplan-Meier survival curve analysis, after internal validation, patients belonging to the KLK8-high expression group had significantly (P \ 0.001) shorter DFS intervals, compared to patients in the KLK8-low expression group. Cox univariate regression analysis confirmed the significantly poorer DFS of patients with high-KLK8 expression, analyzed as a continuous variable ([HR] = 3.28, P \ 0.001). Although these results seem to be contradictory with the observed downregulation of KLK8 mRNA expression in BC tissues compared to histologically normal counterparts, this phenomenon is, in fact, common and it was previously reported for other KLK family members in BC studies. For instance KLK5, KLK7, and KLK14 are all reported to be downregulated in the BC tissues relative to non-cancerous ones. However, the expression of these KLKs has been associated with poor prognosis of BC patients [42] [43] [44] . The question that remains is how these KLKs are associated with BC progression, since their mRNA levels appear to be downregulated in BC tissues. One possible explanation is that KLK mRNA expression levels might not correlate with protein expression levels in BC tissues, due to a regulation on the translational level [22] . Another possible explanation comes from a microarray study by Tripathi et al., which showed that global gene expression abnormalities occur in normal epithelium of BC patients [45] . Interestingly, Schummer et al., revealed that a number of genes, usually associated with cancer pathways, are expressed at lower levels in BC compared to normal breast tissue [46] . Furthermore, growing evidence suggests, that primary tumor growth induces molecular changes in adjacent tissues that are believed to support cancer progression [47] .
Multivariate Cox regression model adjusted for important clinicopathological parameters such as TNM stage, nodal status, BC molecular subtype, patients' age, and histological grade, identified KLK8 expression ([HR] = 2.69, P = 0.003) as a strong and independent indicator of unfavorable outcome with regard to DFS, for BC patients. Most importantly, KLK8 mRNA expression retained its independence as an indicator of poor DFS for BC patients ([HR] = 2.00, P = 0.029), irrespective of the post-operative therapeutic modalities used. It should be noted here that KLK8 protein expression was previously identified as a predictor of adverse progression-free survival in patients with advanced ovarian cancer [18] , while KLK8 type 4 splice variant is an independent indicator of poor OS in lung cancer patients [20] .
Despite performing internal validation, a more rigorous verification of our observations through external validation on heterogeneous, larger, and multicentric datasets, is among our future goals in order to strengthen the significance of our findings and to confirm KLK8 significance as a BC biomarker. Another interesting future perspective would be the assessment of KLK8 protein expression in bodily fluids, such as nipple aspirate fluid or serum from BC patients, and its clinical evaluation as a soluble biomarker for non-invasive diagnosis, prognosis, and prediction or monitoring of chemotherapy response in BC.
Conclusions
Our study is the first to show that high-KLK8 mRNA levels are significantly associated with advanced TNM stage, non-luminal (TNBC and HER2 overexpressing) molecular subtypes of BC, and with poor clinical outcome, in terms of DFS, of BC patients. Most importantly we show that KLK8 expression is an independent indicator of unfavorable outcome for BC patients.
